The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

The use of RBL, a fecal microbiota-based live biotherapeutic, was safe and efficacious for recurrent CDI prevention in a large cohort of adults with common comorbidities.

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Candidate CDI vaccine PF-06425090 was not effective for primary infection prevention but it was efficacious against CDI-related medical attention and antibiotic intervention.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

We recently compiled a list of the 7 Best High Short Interest Stocks To Invest In. In this article, we are going to take a ...

The bacterial infection is easily passed from person to person. It is thought to affect around one-third of the U.S.

The following is a summary of “Rational design of live biotherapeutic products for the prevention of Clostridioides difficile infection,” published in the September 2024 issue of Infectious Disease by ...

For example, because the pathogens of many gut infections, including cholera and Clostridioides difficile, germinate only in the presence of particular conjugated bile acids, this mouse could be a ...